Search results: (10000)
News Comparison of Clinical Outcomes of TKA Implantation: ATTUNE vs. SIGMA
The ATTUNE total knee arthroplasty (TKA) system was introduced to the market in 2013 as a successor to the popular SIGMA system. The new type of knee endoprosthesis is designed to provide better stability and mobility than the previous implant. Several studies have evaluated the clinical outcomes of the implantation of both types of endoprostheses.
News Efficacy and Speed of Pain Relief in Rheumatoid Arthritis When Adding Baricitinib to Methotrexate
The phase III clinical trial RA-BEAM conducted in patients with rheumatoid arthritis (RA) inadequately controlled by methotrexate demonstrated the benefit of adding baricitinib or adalimumab compared to placebo in terms of reducing the number of swollen joints. However, baricitinib showed greater pain relief starting from week 1 compared to placebo and from week 2 compared to adalimumab. Thus, the recently published results of an analysis using the data from this study aimed to compare the proportion of patients who achieved certain pain relief thresholds, the time required for pain relief, and the relationship between the presence of inflammation and pain.
News The Link Between Various Sleep Disorders and the Onset of Depression: What Findings Did the Population Study in Denmark Bring?
A Danish population study published in June 2019 examined the link between different types of sleep disorders and the risk of developing depression. Which disorders confirmed this link after evaluating data from tens of thousands of patients?
News Pain Relief and Functional Score Improvement in Patients with Low Rheumatoid Arthritis Activity: Baricitinib vs. Adalimumab
In patients with rheumatoid arthritis, pain and functional impairment may persist even with good disease activity control. An exploratory analysis of the RA-BEAM study compared the effects of baricitinib, adalimumab, and placebo added to methotrexate on residual pain and functional scores in patients with rheumatoid arthritis (RA) who achieved remission or low disease activity with this treatment.
News Persistence of Treatment with Secukinumab and Ixekizumab in Patients with Moderate to Severe Psoriasis
Although IL-17 targeted drugs are increasingly used in the treatment of moderate to severe psoriasis, we currently have limited data on patient persistence with these treatments.
News How to Manage Thromboprophylaxis in Obese and Extremely Obese Patients?
Doctors often address the question of how to dose thromboprophylaxis in overweight individuals. The goal is to ensure effective protection against thrombotic complications in stressful situations, such as hospitalization or surgical procedures, without increasing the risk of bleeding.
News Positive Effect of Pregabalin Not Only on Neuropathic Pain in Patients with Spinal Cord Injury
Spinal cord injury is often accompanied by painful conditions. A study published in the prestigious journal Neurology demonstrated that administering pregabalin to these patients can bring more than just pain relief.
News Valproate for Acute Mania: Is Practice Really Evidence-Based and Recommended?
Authors from the University of Western Ontario conducted an audit in an acute psychiatric intake unit to determine whether the prescription of valproate there corresponded to evidence-based recommendations.
News Metformin and Cardiovascular Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease
Diabetes mellitus is a serious chronic disease that, due to its ever-increasing prevalence, poses a significant problem for society in developed countries. The main cause of morbidity and mortality in patients with type 2 diabetes is cardiovascular disease, and the likelihood of their occurrence is increased by concomitant chronic kidney disease. In current diabetes treatment, antidiabetic agents are thus preferred, as they also provide cardioprotective and nephroprotective effects.
News Are SGLT2 Inhibitors Only Suitable for the Treatment of Diabetes?
SGLT2 inhibitors, or gliflozins, are effective antidiabetic drugs that have shown nephroprotective and cardioprotective effects in diabetics, repeatedly demonstrated in clinical trials. At the European Cardiology Congress in September 2019 in Paris, results were presented from the DAPA-HF study, where dapagliflozin became the first SGLT2 inhibitor to show benefits in patients with heart failure with reduced ejection fraction of the left ventricle, regardless of whether they had type 2 diabetes or not. The study thus offered a completely new perspective on the treatment of heart failure.
News Meta-analysis of Incidence of Infusion Reactions to Anti-EGFR Antibodies in Patients with mCRC
The application of antibodies against the epidermal growth factor receptor (EGFR), administered in slow infusions mainly as part of the treatment for metastatic colorectal cancer (mCRC), may be accompanied by infusion reactions or hypersensitivity reactions.
News Low-Molecular-Weight Heparin as Adjuvant Therapy in Small-Cell Lung Cancer − Results of the RASTEN Study
Several studies and meta-analyses in the past have pointed to a possible positive effect of low-molecular-weight heparins (LMWH) in the treatment of cancer. The RASTEN study therefore focused on the potential effect of enoxaparin in patients with small-cell lung cancer (SCLC).
News Treatment of Immune Thrombocytopenia: Choice of TPO Mimetics in Clinical Practice
Real-world data show that the administration of thrombopoietin receptor agonists in immune thrombocytopenia leads to a high percentage of treatment responses, and in some patients, it is possible to achieve a stable response without the need for further treatment after discontinuation.
News Current ASH Guidelines for Management of ITP 2019 − Recommendations for Newly Diagnosed ITP in Adults
The American Society of Hematology (ASH) published current guidelines for immune thrombocytopenia (ITP) at the end of 2019, where a panel of experts attempted to define evidence-based recommendations for the management of these patients.
News Pharmacotherapy of Hip Osteoarthritis with Unsaponifiable Soy and Avocado Oil – Insights from the ERADIAS Study
Unsaponifiable soy and avocado oil is indicated for the symptomatic therapy of hip and knee osteoarthritis. Research primarily focuses on the effectiveness of the drug in patients with knee osteoarthritis; there are significantly fewer studies focused on the hip area and their results are not consistent. For this reason, an extensive study was conducted by French authors evaluating the impact of the drug on the progression of hip osteoarthritis in several hundred patients over the medium term.